Literature DB >> 10888732

Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection.

D McNamara1, C O'Morain.   

Abstract

Helicobacter pylori is a recognized cause of a variety of gastroduodenal pathology. The high prevalence of both H pylori infection and related diseases within the community warrants its consideration as a public health care issue. The availability of reliable and safe noninvasive diagnostic techniques coupled with the development of effective and tolerable treatments has enabled primary health care personnel to manage this infection actively. The role of the primary care physician in the future management of H pylori infection is thus of central importance. The wealth of evidence produced by over 15 years of research into H pylori has expanded the list of disease associations and treatment benefits as well as elucidated the pathophysiological mechanisms involved. As a result, there has been a growing need to harmonize this information with clinical practice and to provide direction for the appropriate management by both specialists and general practitioners. Several national guidelines have been produced. The areas relating to H pylori infection that they considered and their recommendations vary. In 1994, the National Institutes of Health produced globally accepted recommendations for the management of H pylori-related peptic ulceration. The broader role of H pylori as a gastroduodenal pathogen and a public health care issue was not addressed. Recently, European and Canadian consensus guidelines have been published that identified overall management issues, including the role of primary and specialist care, and considered the appropriateness of employing eradication therapy for the spectrum of conditions in which H pylori has a direct or indirect association based on the available information. These guidelines, while in agreement regarding many issues, differ considerably in their recommendations for primary health care and regarding central issues such as the management of dyspepsia and gastric cancer. Some variations may reflect differing health care structures as well as the prevalence of both infection and associated diseases. However, the interpretation of evidence produced by recent research contributes to their conflicting statements.

Entities:  

Mesh:

Year:  2000        PMID: 10888732     DOI: 10.1155/2000/604563

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  4 in total

1.  Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays.

Authors:  K A Ryan; L J van Doorn; A P Moran; M Glennon; T Smith; M Maher
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Authors:  Rodrigo Buzinaro Suzuki; Cristiane Maria Almeida; Márcia Aparecida Sperança
Journal:  BMC Gastroenterol       Date:  2012-05-17       Impact factor: 3.067

3.  Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori.

Authors:  Salman R Hasan; Vahabzadeh Vahid; Pahlvanzadah M Reza; Salman R Roham
Journal:  Saudi J Gastroenterol       Date:  2010 Jan-Mar       Impact factor: 2.485

4.  Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Authors:  Rodrigo Buzinaro Suzuki; Rodrigo Augusto Basso Lopes; George Arouche da Câmara Lopes; Tin Hung Ho; Márcia Aparecida Sperança
Journal:  BMC Gastroenterol       Date:  2013-12-04       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.